oligonucleotide routes of administration, in vivo distribution hurdles, what to consider
Published 8 years ago • 557 plays • Length 31:01Download video MP4
Download video MP3
Similar videos
-
31:01
addressing delivery hurdles in the translation of oligonucleotide therapeutics
-
9:25
what are oligonucleotide therapeutics, and how do they work?
-
30:55
nonclinical strategies for oligonucleotide development programs
-
23:35
antisense oligonucleotide therapy
-
25:00
oligonucleotide therapeutic development: pre-clinical and translational considerations
-
1:16:45
antisense oligonucleotides- mechanisms of action and rational design
-
22:47
chemistry of oligonucleotide therapeutics 101
-
59:22
delivery of chemically stabilized rnai molecules to the central nervous system
-
23:23
oligonucleotides as a new therapeutic class: progress report & prescription
-
25:20
oligonucleotide therapeutic development: clinical pharmacology considerations
-
25:14
regulatory applications of a nonclinical database for oligonucleotide therapeutics at u.s. fda
-
20:32
12th annual meeting of the oligonucleotide therapeutic society
-
24:01
new approach for safety evaluation of oligonucleotide therapeutics using rnaseq
-
1:24
how does it work? | oligonucleotide therapies
-
58:52
delivery of macromolecular therapeutics: tackling a billion year old barrier
-
32:24
drug development process - tox, adme, pk/pd, clinical poc and drug approval
-
1:06:45
therapeutic oligonucleotide discovery & development: discovery day 1
-
1:42
oligonucleotide-based therapeutics
-
55:48
therapeutic oligonucleotide discovery & development: development day 2
-
1:28:09
safety of therapeutic oligonucleotides